Landmark BioVentures and G.CLIPS Biotech forge strategic alliance to address critical gaps in drug target engagement

Partnership brings into sharper focus need to integrate target engagement and candidate profiling solutions to optimize drug development process and increase likelihood of success

Basel, Switzerland, and Toulouse, France, April 23, 2025 – Landmark BioVentures (LBV), an integrative corporate and drug development company using resources smartly to advance multiple innovative therapies, and G.CLIPS Biotech, a technology platform company changing the paradigm in targets by enabling the discovery, generation and validation of conformation-sensitive and pathology-sensitive drug candidates, today announce a strategic alliance. Financial terms were not disclosed. 

The partnership addresses a critical gap in early-stage drug development, where target engagement and physiopathology – a cornerstone of therapeutic efficacy and safety – is often underestimated, due to technical, financial and/or strategic constraints. Addressing this gap early helps to de-risk the overall drug development process, gaining significant efficiencies, with both time and cost savings.

This agreement deepens the existing collaboration between LBV and G.CLIPS, founded on shared scientific and strategic values, which started in 2023. 

LBV has validated G.CLIPS’ innovative platform firsthand, demonstrating the ability of the technology to provide novel, cost-effective solutions for target engagement and candidate profiling to address critical gaps in early-stage drug development. By formalizing this partnership, G.CLIPS now becomes a long-term partner in LBV’s innovation ecosystem, supporting lead candidate nomination, deepening the understanding of specific therapeutic mechanisms of action and defining the target product profile of drug candidates.

“Target engagement isn’t just a box to check; it is the cornerstone of successful drug development,” said Zaki Sellam, co-founder and CEO of Landmark BioVentures. “This strategic alliance with G.CLIPS equips our nexus of companies with tools that were previously inaccessible, turning a traditional bottleneck into a strategic advantage.”

“We’re excited to deploy our unique technology platform across LBV’s nexus through this alliance. LBV’s integrative model aligns perfectly with our approach, allowing us to demonstrate G.CLIPS’ value as an embedded strategic partner in drug development programs,” said Rosie Dawaliby, co-founder and CEO at G.CLIPS Biotech, “This collaboration provides the ideal opportunity to showcase the versatility of our target engagement and candidates, profiling solutions while creating significant potential for deeper involvement in LBV’s development pipeline.” 

About Landmark BioVentures AG

Landmark BioVentures is an integrative corporate and drug development company using resources smartly to advance multiple innovative therapies. Anchored by foundational science, LBV uncovers hidden gems with unrealized therapeutic potential by connecting non-obvious dots and taking a strategically-focused active hands-on approach with each nexus company. Led by a seasoned multidisciplinary team of drug developers, entrepreneurs and deal makers, LBV harnesses its specialized and industry-relevant drug development expertise and opportunistic and creative deal-making in resource-constrained environments, to streamline drug development, focusing on holistic value creation and capture.

www.landmarkbioventures.com or LinkedIn

About G.CLIPS Biotech

G.CLIPS Biotech created the first enabling technology to unravel the potential of drug and antibody candidates in a pathology-like format. The company’s G.Screen^® platform is a unique technology with the ability to express, stabilize, select and validate proteins as targets, as well as in vitro pharmacological profiling of drug candidates and target engagement. G.CLIPS provides tailor-made services to pharma, biotech and animal health companies including: 

• Delivery of purified and stabilized targets in the desired conformation and specific environment for screening, immunizations, structural studies, yeast and phage display
• Mechanism of action and functional testing of drugs and antibody candidates on targets stabilized in specific conformation(s) and environment(s)
• Target validation and target engagement of drugs and antibody hits, leads and clinical candidates

www.gclips-biotech.com or LinkedIn